IAM (IAM) is a publicly traded the market company. As of October 15, 2026, IAM trades at $18.66 with a market cap of $0 and a P/E ratio of 0.00. IAM moved +112.30% today. Year to date, IAM is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces IAM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nvidia-backed Iambic Therapeutics jumps in debut after $150 million IPO: Iambic Therapeutics shares rose 19% to $19.08 in their Nasdaq debut after the drug developer raised $150 million in an IPO. The company sold 9.38 million shares at $16 apiece, within its marketed range of $15 to $17.
| Metric | Value |
|---|---|
| Price | $18.66 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 438.43K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
IAM analyst coverage data. Average price target: $0.00.